The Company’s beginnings date back to 1899. Its history of scientific innovation began shortly thereafter with the discovery of epinephrine – a lifesaving medication still widely used today.
In 1912, the first president of Sankyo, Dr. Jokichi Takamine, organized the gift of 3000 cherry trees from Tokyo’s mayor, Yukio Ozaki, to Washington DC where they bloom every spring to the delight of local citizens and visitors to the U.S. capital.
Daiichi Sankyo Company, Ltd. was established in 2005 through the merger of two leading Japanese pharmaceutical companies; Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. Both companies had a great tradition in pharmaceutical research and development and by combining their strengths have become a global pharmaceutical innovator.
This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. Areas of central focus for Daiichi Sankyo research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com
Luitpold Pharmaceuticals, Inc. is proud to be a member company of the Daiichi Sankyo group.